This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Mar 6, 2026
•
8 min read
🧬 Portal Innovations to open 30,000-square-foot biotech incubator in Salt Lake City by 2027, Zealand Pharma's petrelintide shows placebo-like tolerability with 10.7% weight loss in Ph2 obesity trial, BioDuro + Cenra API Solutions form Taiwan joint venture for end-to-end API manufacturing services
Mar 5, 2026
🧬 Roche invests $484M in South Korea to establish global clinical trial ecosystem, Ireland maintains biopharma investment appeal despite US tariff uncertainty and geopolitical trade tensions, UK invests $64M in NHS equipment to expand clinical trial access to underserved communities, ARPA-H launches $158M program for first-ever lymphatic system drug development, Blackstone Life Sciences + Teva Pharmaceutical partner on gut disease drug duvakitug with $400M commitment, Nvidia, Droplet Biosciences partner on AI-accelerated genomic analysis for lymph-based liquid biopsy testing
Mar 4, 2026
20 min read
🧬 Novo Nordisk commits $506M to upgrade Irish facility for oral Wegovy production ahead of European approval, Alveus Therapeutics raises $37M Series A extension for obesity drug development, Atrium Therapeutics spins out of Novartis-acquired Avidity with $270M to develop RNA medicines for rare heart diseases, Roche's fenebrutinib (BTK inhibitor) hits Ph3 goals in relapsing multiple sclerosis despite safety concerns, Sanofi + Sino Biopharmaceutical license JAK/ROCK inhibitor rovadicitinib globally, $135M upfront +$1.53B total, Earendil Labs + WuXi XDC partner on next-gen ADC linker technology + $885M total deal, Moderna's mCombriax combination flu and COVID-19 vaccine wins European drug regulators' positive recommendation for ages 50+
Feb 27, 2026
🧬 Generate Biomedicines raises $400M IPO - AI drug discovery specialist developing asthma treatments, Asahi Kasei acquires Germany's Aicuris for $920M to boost viral infection R&D portfolio, Eli Lilly's orforglipron (GLP-1) outperforms Novo's Rybelsus in Ph3 diabetes trial on weight loss and blood sugar
Feb 26, 2026
🧬 Novartis selects Denton, Texas for fifth US radiopharmaceutical facility - generating $280M investment and 175 jobs, BreezeBio raises $60M Series B - genetic medicines using specialized nanoparticles, Novo Nordisk + Vivtex collaborate on oral biologics for obesity, up to $2.1B in milestones, Gilead's bictegravir/lenacapivir combo shows Ph2/3 non-inferiority results for human immunodeficiency virus treatment, GSK to buy 35Pharma for $950M - gaining pulmonary hypertension hopeful HS235, Pfizer + Beam Therapeutics global license for liver-targeted gene editing candidate - $1.05B milestone potential
Feb 25, 2026
9 min read
🧬 Western biopharma licensing deals with Chinese companies surge 230% in upfront values - reaching $172M average, Pfizer + Sciwind Biosciences partner on Chinese GLP-1 ecnoglutide commercialization - up to $495M deal, Sanofi and Regeneron's Dupixent (dupilumab) wins FDA approval for allergic fungal rhinosinusitis following Ph3 success
Feb 24, 2026
10 min read
🧬 Gilead to acquire CAR T partner Arcellx for $7.8B ahead of potential anito-cel approval, Generate:Biomedicines plans $425M IPO to bankroll antibody's phase 3 asthma trials, Harbour BioMed + Solstice Oncology license anti-CTLA-4 antibody HBM4003 - $105M upfront + $1.2B total, Fortress Biotech sells FDA priority review voucher for $205M following Zycubo approval, Bora Pharmaceuticals + GSK renew five-year manufacturing agreement covering 335 products worth $250M, FDA publishes draft guidance for personalized genetic medicines targeting rare diseases through Plausible Mechanism Pathway
Feb 23, 2026
🧬 Candel Therapeutics $100M royalty deal to fund prostate cancer drug launch, Vanda Pharmaceuticals wins FDA approval for Bysanti (milsaperidone) targeting bipolar I disorder and schizophrenia, Virion Therapeutics reports sustained anti-hepatitis B virus immunity from single VRON-0200 dose in Ph1 study
Feb 20, 2026
🧬 Insmed CEO defends "audacious" $1B Brinsupri 2026 sales projection after strong Q4 launch performance, Altesa BioSciences raises $75M Series B - advancing lung drug vapendavir, Merck & Co.'s Enflonsia (clesrovimab) shows positive Ph3 results for second-season respiratory syncytial virus prevention
Feb 19, 2026
🧬 J&J to build $1B cell therapy plant in Pennsylvania, creating 500 jobs as part of their $55B US investment plan, Danaher buys patient monitoring specialist Masimo in $9.9B deal to strengthen diagnostics portfolio, Korsana Biosciences launches with $150M series A to advance next-generation anti-amyloid Alzheimer's antibody KRSA-028, Eli Lilly's Zepbound (tirzepatide) plus Taltz combination shows Ph3 efficacy in moderate-to-severe plaque psoriasis, Merck & Co. + Mayo Clinic partner on AI drug discovery using multimodal patient data platform, Novartis + Unnatural Products partner on cardiovascular macrocyclic peptides for $100M upfront and $1.7B in biobucks, EIR Biopharma targets $17M IPO - preclinical eye disease drug development
Feb 18, 2026
🧬 Japan-based Innovacell aims for $92M IPO, cell therapy for urge fecal incontinence treatment, Stada invests €85M ($100.8M) to build Saudi Arabia production facility serving Middle East region by 2030, Sanofi and Teva report durable 44-week Ph2 results for duvakitug targeting TL1A in inflammatory bowel disease, RoukenBio + AVS Bio partner to improve antibody development through early discovery and preclinical research, Novartis + Niowave partner for long-term supply of Actinium-225 radioisotope for targeted cancer therapies, GSK's Exdensur (depemokimab) wins EU approval for severe asthma and chronic rhinosinusitis with nasal polyps
Feb 17, 2026
🧬 Vertex Pharmaceuticals and CRISPR Therapeutics project $500M combined revenue for Casgevy gene therapy by 2026, Eli Lilly stockpiles $1.5B orforglipron inventory ahead of FDA approval while Novo expands Wegovy pill internationally, Nektar Therapeutics raises $460M public offering, clinical-stage immunotherapy medicine development, Eli Lilly's Retevmo (selpercatinib) shows Ph3 success in early-stage RET fusion-positive non-small cell lung cancer, Zeon Corporation invests in Chemify to accelerate digital chemistry innovation and develop new materials, CSL Seqirus receives Australian approval for neffy (adrenaline) nasal spray treating anaphylaxis in adults and children
